Why is PALI down?
Down 25% over the five sessions to Nov 20 while the S&P 500 fell 9%.
- Palisade Bio fell 25% in those sessions while biotech stocks fell a median 9%:
−3Long-term trend
Down 25% over the five sessions to Nov 20 while the S&P 500 fell 9%.
−3Long-term trend
PALI's Quality Score fell 1 point on Fri, Nov 20, to -9.
Follow PALI's trial news. Pro members can get an alert when Palisade Bio files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 28 times as many shares as a year ago |
| Latest filing | 8-K, Nov 10 |
Expected to report Tue Feb 9, after the close
About 17 quarters
Director Robert Baltera Jr. bought 50,000 shares on Nov 17. 10 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
PALI is #254 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 254 |
Expected to report Tue Feb 9, after the close (in 80 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.07 a share, from $0.38.
“The increase primarily reflects expenses associated with advancing PALI-2108 into Phase 2 clinical development, including clinical trial start-up activities, manufacturing and clinical supply, and supporting preclinical and translational research, as well as higher employee-related expenses, including increased non-cash stock-based compensation expense.”
PALI's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The year-over-year increase reflects the Company’s expanded operating activities and higher employee-related expenses, including increased non-cash stock-based compensation expense.”
From its results filing (SEC filing · Nov 10)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 10, 2026 | -1.8% | +3.5% | -10.6% |
| Aug 10, 2026 | -2.4% | +1.9% | +2.4% |
| May 12, 2026 | 0.0% | -2.6% | -5.7% |
Sales fell every year from 2017 to 2025, to $0. It lost money in each of the seven years.
RSI 24.6, MACD below signal, below both averages. Not scored.
2 insiders bought $329K across 9 filings, and 2 insiders sold $410K across 2 filings, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
“As a clinical biopharmaceutical company, we face competition from a wide array of companies in the pharmaceutical and biotechnology industries.”
PALI scores -9 today, which Breakaway calls Poor. It is #254 of 273 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 25% over the five sessions to Nov 20 while the S&P 500 fell 9%. Cash lasts about 17 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
PALI scores -9 today, which Breakaway calls Poor (below zero). That is #254 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PALI's -9.
2 insiders bought $329K across 9 filings, and 2 insiders sold $410K across 2 filings, in the last 6 months. The newest is Robert Baltera Jr., Director, who bought $50K on Nov 17. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.